- UHRA Home
- Browsing by Author
Browsing by Author "Storey, Robert F."
Now showing items 1-6 of 6
-
Antithrombotic therapy in diabetes: Which, when, and for how long?
Ajjan, RA; Kietsiriroje, N; Badimon, L; Gorog, Diana; Angiolillo, Dominick J.; Russel, D; Rocca, Bianca; Storey, Robert F. (2021-03-25)Cardiovascular disease remains the main cause of mortality in individuals with diabetes mellitus (DM) and also results in significant morbidity. Premature and more aggressive atherosclerotic disease, coupled with an enhanced ... -
Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a Joint Position Paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI)
Gorog, Diana; Price, Susanna; Sibbing, Dirk; Baumbach, Andreas; Capodanno, Davide; Gigante, Bruna; Halvorsen, Sigrun; Huber, Kurt; Lettino, Maddalena; Leonardi, Sergio; Morais, Joao; Rubboli, Andrea; Siller-Matula, Jolanta M; Storey, Robert F.; Vranckx, Pascal; Rocca, Bianca (2020-02-12) -
Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium
Gorog, Diana A.; Storey, Robert F.; Gurbel, Paul A.; Tantry, Udaya S.; Berger, Jeffrey S.; Chan, Mark Y.; Duerschmied, Daniel; Smyth, Susan S.; Parker, William A.E.; Ajjan, Ramzi A.; Vilahur, Gemma; Badimon, Lina; Berg, Jurrien M.ten; Cate, Hugo ten; Peyvandi, Flora; Wang, Taia T.; Becker, Richard C. (2022-07)Coronavirus disease 2019 (COVID-19) predisposes patients to thrombotic and thromboembolic events, owing to excessive inflammation, endothelial cell activation and injury, platelet activation and hypercoagulability. Patients ... -
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis.
Gorog, Diana; Ferreiro, Jose Luis; Ahrens, Ingo; Ako, Junya; Geisler, Tobias; Halvorsen, Sigrun; Huber, Kurt; Jeong, Young-Hoon; Navarese, Eliano P; Rubboli, Andrea; Sibbing, Dirk; Siller-Matula, Jolanta M; Storey, Robert F.; Tan, Jack W C; Berg, Jurrien M.ten; Valgimigli, Marco; Vandenbriele, Christophe; Lip, Gregory Y H (2023-07-20)Conventional dual antiplatelet therapy (DAPT) for patients with acute coronary syndromes undergoing percutaneous coronary intervention comprises aspirin with a potent P2Y purinoceptor 12 (P2Y12) inhibitor (prasugrel or ... -
Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes
Storey, Robert F.; Gurbel, Paul A.; Berg, Jurrien ten; Bernaud, Corine; Dangas, George D.; Frenoux, Jean Marie; Gorog, Diana A.; Hmissi, Abdel; Kunadian, Vijay; James, Stefan K.; Tanguay, Jean Francois; Tran, Henry; Trenk, Dietmar; Ufer, Mike; van der Harst, Pim; Van't Hof, Arnoud W.J.; Angiolillo, Dominick J. (2020-09-01)Aims To study the pharmacodynamics and pharmacokinetics of selatogrel, a novel P2Y12 receptor antagonist for subcutaneous administration, in patients with chronic coronary syndromes (CCS). Methods In this double-blind, ... -
Thrombogenicity and Antithrombotic Strategies in Structural Heart Interventions and Nonaortic Cardiac Device Therapy—Current Evidence and Practice
Geisler, Tobias; Jorbenadze, Rezo; Popov, Aron-Frederik; Mueller, Karin L.; Rath, Dominik; Droppa, Michal; Schreieck, Juergen; Seizer, Peter; Storey, Robert F.; Kristensen, Steen D.; Rubboli, Andrea; Gorog, Diana; Aradi, Daniel; Sibbing, Dirk; Huber, Kurt; Gawaz, Meinrad; Berg, Jur Ten (2019-08-17)As the number of, and the indications for, structural heart interventions are increasing worldwide, the optimal secondary prevention to reduce device thrombosis is becoming more important. To date, most of the recommendations ...